Rectify Pharma
@RectifyPharma
Followers
129
Following
4
Media
104
Statuses
124
Developing Positive Functional Modulators (PFMs) to restore and enhance membrane protein function and address the underlying cause of serious diseases.
Boston, MA
Joined September 2021
Today, we announced selection of our lead small molecule #PFM for treatment of hepatobiliary diseases by improving bile composition and enhancing bile flow. We look forward to advancing to first-in-human clinical trials for primary sclerosing cholangitis.
1
1
6
Our CMO, Dr. Pol Boudes, is looking forward to connecting with peers at the Cholestatic Liver Disease Summit this week to help the community bridge knowledge gaps and develop scientific collaborations.. Learn more about the summit:
0
0
0
This month, our team stepped out of the office to cheer on the Red Sox at Fenway Park! A walk-off home run made the day even sweeter. Moments like these remind us to stay strong as a team, on and off the field. Here’s to more wins together! #RedSoxNation
0
0
0
#ICYMI: Our CEO, @r_devraj, joined Sam Kessel on the @NucleateHQ podcast to talk target validation, PFMs, and the mission driving Rectify’s work in #PSC and beyond.. 🎧 Tune in:
0
0
1
Are you attending @IAmBiotech #BIO2025 in Boston? Our team is excited to connect with global industry leaders at this premier event. Let’s connect!. 📢 Learn more:
0
0
0
We presented at the 62nd @ERAkidney Congress, sharing translational data on our ABCC6-targeting #PFM for chronic kidney disease and vascular calcification, key drivers of cardiovascular morbidity. Missed it? View the presentation here: #CKD
0
0
0
#ICYMI: Our CEO, @r_devraj, joined Sam Kessel on the @NucleateHQ podcast to talk target validation, PFMs, and the mission driving Rectify’s work in #PSC and beyond. 🎧 Tune in:
0
1
1
We’re presenting at the 62nd @ERAkidney Congress! Our translational data on ABCC6-targeting #PFM for chronic kidney disease & vascular calcification, a key driver of morbidity in cardiovascular disease. Join us at the CKD session! More info here:
0
0
0
#DYK Healthy bile flow and composition are key to #BiliaryHealth—supporting digestion, waste removal, and protecting the liver. Disruptions, especially in bile salts and phospholipids, are central to diseases like #PrimarySclerosingCholangitis. Learn more:
0
0
0
We’re attending the 62nd @ERAkidney Congress June 4–7! We’ll present new transitional data from our cardio-renal-metabolic program addressing critical unmet needs in kidney health. More on our presentation: #ERA25
0
1
2
At #EASLCongress 2025 we’re presenting data that demonstrates the potential for a B4/BSEP PFM to address the core pathology of multiple liver & biliary diseases, incl. #PrimarySclerosingCholangitis. Read more:
1
1
2
Dr. Eric Bell will present on our lead program #PrimarySclerosingCholangitis at #EASLCongress 2025 during the Immune-mediated & Cholestatic Diseases session. We look forward to engaging with experts & sharing insights on advancing treatments. Read more:
0
0
0
Our pipeline of #PositiveFunctionalModulators is set to revolutionize treatment by restoring membrane protein function. Our #PFMs target programs in #hepatobiliary, #cardiorenal, & #neurodegenerative conditions, offering renewed hope. Learn more:
0
1
0
Proud to see our work featured in Communications Biology! The study provides structural insights into mutation-driven BSEP misfolding & dysfunction, advancing our development of #PFMs for #PrimarySclerosingCholangitis, PFIC2 & related conditions. More here:
0
0
0
Join our CMO, Pol Boudes, at the Chief Medical Officer Summit 360˚next month! He’ll discuss optimizing clinical trials through streamlined operations and connects with CMOs across indications, modalities, company stages, & more. Learn more: #CMO360
0
0
0
Rectify President & CEO @r_devraj joins @rahulc on this week’s episode of #Biotech2050 to share how we’re rethinking small-molecule drug development—starting with RTY-694 for PSC. Listen now:
How do you build a biotech startup that thrives? 🚀 In this #Biotech2050 episode, @r_devraj President & CEO of @RectifyPharma joins @rahulc to discuss drug discovery, biotech innovation & capital strategy. Listen now: #DrugDiscovery #Pharma #Biopharma
0
0
3
We're proud to have Youhwa Jo on our team. As a Senior Research Associate II, she tackles scientific challenges with grit & urgency, executing assays & studies with rigor.She's also a supportive, collaborative colleague whose commitment to innovation makes a difference every day!
0
0
1
#ICYMI: Our CMO, Pol Boudes, MD, joined @PharmaTechFocus to discuss refined patient categorization & innovative diagnostics for #MASH. His insightful discussion paves the way for more effective trials & less invasive fibrosis staging. . Read more here:
0
0
0
Our CEO, @r_devraj, joined the @Xtalks podcast to discuss oral, small molecule #PFMs for diseases caused by membrane protein dysfunction, drug discovery challenges & their impact on #PSC, #CKD, & neurodegenerative disorders. ⬇️ Listen down below!.
In this episode, Dr. Rajesh Devraj, CEO of @RectifyPharma, speaks about important considerations in early drug development, advancing treatments in the liver disease landscape and being a disruptor in the biotech space. Listen now at 🎙️
0
0
1
#Rare doesn't mean alone! This #RareDiseaseDay, we stand with the #PrimarySclerosingCholangitis (PSC) community and advocates such as PSC Partners Seeking a Cure, who work tirelessly to create a better future for those living with #PSC. More here:
5
0
0